Cargando…
RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral
Autores principales: | Jain, Sidharth, Rego, Samantha, Park, Steven, Liu, Yiran, Parn, Simone, Savsani, Kush, Perlin, David S., Dakshanamurthy, Sivanesan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627224/ https://www.ncbi.nlm.nih.gov/pubmed/36321336 http://dx.doi.org/10.1002/ctm2.1098 |
Ejemplares similares
-
SARS-CoV-2 Omicron (BA.1 and BA.2) specific novel CD8+ and CD4+ T cell epitopes targeting spike protein
por: Parn, Simone, et al.
Publicado: (2022) -
Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism
por: Policard, Martine, et al.
Publicado: (2021) -
Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism
por: Policard, Martine, et al.
Publicado: (2021) -
A New Epitope Selection Method: Application to Design a Multi-Valent Epitope Vaccine Targeting HRAS Oncogene in Squamous Cell Carcinoma
por: Savsani, Kush, et al.
Publicado: (2021) -
A Peptide Vaccine Design Targeting KIT Mutations in Acute Myeloid Leukemia
por: Kim, Minji, et al.
Publicado: (2023)